Long-Term Efficacy of Dapagliflozin as Add-On to Metformin (MET) in T2DM Inadequately Controlled with MET Alone

被引：0
|
作者：
Bailey, Clifford J.
Gross, Jorge L.
Yadav, Manoj
Iqbal, Nayyar
Mansfield, Traci A.
List, James F.
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
988-P
引用
收藏
页码：A271 / A271
页数：1
相关论文
共 50 条
  • [21] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    DIABETES, 2014, 63 : A310 - A310
  • [22] Dapagliflozin (DAPA) Reduces HbA1c in Asian Patients with T2DM after Metformin (MET) Failure
    Yang, Wenying
    Han, Ping
    Liu, Beijing
    Mansfield, Traci
    T'Joen, Caroline L.
    Iqbal, Nayyar
    Ptaszynska, Agata
    DIABETES, 2014, 63 : A279 - A279
  • [23] Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 104-week VERTIS MET Trial
    Gallo, S.
    Charbonnel, B.
    Goldman, A.
    Shi, H.
    Huyck, S.
    Darekar, A.
    Lauring, B.
    Terra, S. G.
    DIABETOLOGIA, 2018, 61 : S303 - S304
  • [24] The efficacy and safety of metformin alone or as an add-on therapy to insulin in pregnancy with GDM or T2DM: A systematic review and meta-analysis of 21 randomized controlled trials
    He, Ke
    Guo, Qing
    Ge, Jun
    Li, Jingxin
    Li, Caixia
    Jing, Zeng
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (02) : 168 - 177
  • [25] Efficacy of canagliflozin (CANA) in combination with metformin (MET) in patients with T2DM: Results from 3 studies
    Qiu, Rong
    Xie, John
    Hamilton, Gill
    Canovatchel, William
    Fegade, Mayuresh
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S118 - S118
  • [26] THE IMPACT OF ALTERNATIVE ESTIMATES OF DISUTILITIESASSOCIATED WITH HYPOGLYCEMIA ON NET QALYS: CANAGLIFLOZIN VERSUS SITAGLIPTIN AS ADD-ON THERAPY IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON A BACKGROUND OF METFORMIN (MET) PLUS SULFONYLUREA (SU) IN THE CANADIAN SETTING
    Yoong, K.
    Willis, M.
    Johansen, P.
    Yim, C.
    Teschemaker, A.
    Neslusan, C.
    VALUE IN HEALTH, 2014, 17 (03) : A190 - A190
  • [27] Saxagliptin and met formin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with met formin
    Stenlof, Kaj
    Raz, Itamar
    Neutel, Joel
    Ravichandran, Shoba
    Berglind, Niklas
    Chen, Roland
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (10) : 2355 - 2363
  • [28] Therapeutic Efficacy & Long-term Treatment Outcome of DPP- 4 Inhibitors as an add-on Therapy with Metformin and Sulfonylureas in T2DM Patients at GP Clinics of Southern Odisha
    Mohanty, Premakanta
    Panda, Chinmaya Debasis
    Pradhan, Pradyut Kumar
    JOURNAL OF RESEARCH IN MEDICAL AND DENTAL SCIENCE, 2022, 10 (06): : 117 - 123
  • [29] Quality Measure Outcomes with Dapagliflozin (DAPA) Add-on to Metformin (MET) or Insulin (INS) in Patients with Type 2 Diabetes (T2D)
    Mansfield, Traci
    Bell, Kelly
    Rezvani, Geoffrey
    Shatskov, Alla
    Sheehan, John J.
    DIABETES, 2016, 65 : A307 - A307
  • [30] Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial
    Gallo, Silvina
    Charbonnel, Bernard
    Goldman, Allison
    Shi, Harry
    Huyck, Susan
    Darekar, Amanda
    Lauring, Brett
    Terra, Steven G.
    DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 1027 - 1036
12345